Propofol
| Propofol | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 178.27 g/mol [1] |
| Appearance | Light-straw-colored liquid [1] |
| Density | 0.955 g/cu cm @ 20 °C [1] |
| Melting point | 18 °C [1] |
| Boiling point | 256 °C [1] |
| Solubility | 124 mg/L [1] |
| Predicted LogP | 3.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C12H18O |
| IUPAC name | 2,6-di(propan-2-yl)phenol |
| SMILES | CC(C)C1=C(C(=CC=C1)C(C)C)O |
| InChI | InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3 |
| InChIKey | OLBCVFGFOZPWHH-UHFFFAOYSA-N |
| CAS number | 2078-54-8 |
| UNII | YI7VU623SF |
| PubChem CID | 4943 |
| Pharmacokinetics[] | |
|---|---|
| Onset | * Intravenous: 15–30 seconds[3] |
| Elimination half-life | 1.5–31 hours |
| Duration of action | ~5–10 minutes |
| Metabolism | Liver glucuronidation |
| Excretion | Liver |
| Routes of administration | Intravenous |
| Dependence liability | Physical: Very high , Psychological: no data |
| Addiction liability | Moderate[4] |
Propofol (also known as 2,6-diisopropylphenol, Diprivan, Disoprofol, Disoprivan, Fresofol, Rapinovet, Ampofol, 2,6-Bis(1-methylethyl)phenol, Propofolum or Phenol, 2,6-bis(1-methylethyl)-) is a anaesthetic, depressant and opioid substance of the phenol class.
Chemistry
Stereochemistry []
Propofol is achiral.
Druglikeness
Lipinski's rule of five
Propofol matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- anesthetics (N01)
- anesthetics, general (N01A)
- other general anesthetics (N01AX)
- (N01AX10)
- propofol (N01AX10)
MeSH Classification
Mechanism of action []
The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 84 |
|---|---|---|
| GABRA2 | shared target | 81 |
| GABRA3 | shared target | 81 |
| GABRA4 | shared target | 81 |
| GABRA5 | shared target | 81 |
| GABRA6 | shared target | 81 |
| GABRB1 | shared target | 81 |
| GABRB2 | shared target | 81 |
| GABRB3 | shared target | 81 |
| GABRD | shared target | 81 |
| GABRE | shared target | 81 |
| GABRG1 | shared target | 81 |
| GABRG2 | shared target | 81 |
| GABRG3 | shared target | 81 |
| GABRP | shared target | 81 |
| GABRQ | shared target | 81 |
Medical side effects []
157 side effects listed on drug labels in SIDER 4.1 (propofol).
- Abdominal pain
- Respiratory acidosis
- Amblyopia
- Anaphylactic shock
- Anaphylactoid reaction
- Angioedema
- Anxiety
- Apnoea
- Arrhythmia
- Asthenia
- Fatigue
- Atrial fibrillation
- Atrioventricular block
- Block heart
- Coagulopathy
- Bronchospasm
- Bundle branch block
- Cardiac output decreased
- Chest pain
- Confusional state
- Feeling abnormal
- Cough
- Dehydration
- Delirium
- Depression
- Diarrhoea
- Diplopia
- Dizziness
- Syncope
- Dysgeusia
- Dyspnoea
- Ear pain
- Oedema
- Epilepsy
- Dermatitis
- Rash
- Extravasation
- Body temperature increased
- Flushing
- Hallucination
- Headache
- Cardiac arrest
- Cardiac failure
- Haemorrhage
- Haemoglobin
- Hiccups
- Hyperglycaemia
- Hyperkalaemia
- Hyperlipidaemia
- Hypertension
- Hyperventilation
- Hypotension
- Conversion disorder
- Laryngospasm
- Leukocytosis
- Muscle spasms
- Hypertonia
- Hypotonia
- Muscle relaxant therapy
- Muscle rigidity
- Myocardial infarction
- Acute coronary syndrome
- Nausea
- Nystagmus
- Oliguria
- Pain
- Stinging
- Pain in extremity
- Pancreatitis
- Paraesthesia
- Tingling sensation
- Pharyngitis
- Phlebitis
- Supraventricular extrasystoles
- Pruritus
- Pulmonary oedema
- Renal failure
- Rhabdomyolysis
- Convulsion
- Chills
- Salivary hypersecretion
- Sneezing
- Shock
- Loss of consciousness
- Tachycardia
- Supraventricular tachycardia
- Thrombosis
- Tinnitus
- Tremor
- Erythema
- Redness
- Urticaria
- Ventricular fibrillation
- Ventricular tachycardia
- Vomiting
- Wheezing
- Dry mouth
- Urinary retention
- Arrhythmia supraventricular
- Agitation
- Mood swings
- Affect lability
- Drug withdrawal syndrome
- Musculoskeletal stiffness
- Stiffness
- Nuchal rigidity
- Anticholinergic syndrome
- Blood urea increased
- Blood creatinine increased
- Ventricular extrasystoles
- Ventricular bigeminy
- Hypomagnesaemia
- Drug effect increased
- Intracranial pressure increased
- Myocardial ischaemia
- Opisthotonus
- Eye pain
- Metabolic acidosis
- Myalgia
- Musculoskeletal discomfort
- Muscle twitching
- Tachypnoea
- Thinking abnormal
- Mental disability
- Abnormal dreams
- Respiratory depression
- Pulmonary function test decreased
- Euphoric mood
- Right ventricular failure
- Hypoxia
- Hypoventilation
- Sepsis
- Extrasystoles
- Neonatal disorder
- Urine abnormality
- Disinhibition
- Postoperative fever
- Dyskinesia
- Bradycardia
- Nodal arrhythmia
- Neuropathy peripheral
- Electrocardiogram ST segment depression
- Electrocardiogram abnormal
- Chromaturia
- Throat irritation
- Hyperhidrosis
- Upper airway obstruction
- Airway complication of anaesthesia
- Moaning
- Blood osmolarity increased
- Insomnia
- Injection site pain
- Ileus
- Conjunctival hyperaemia
- Somnolence
- Respiratory failure
- Visual impairment
Subjective effects []
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4943, Propofol. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4943
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Propofol. UNII: YI7VU623SF. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/YI7VU623SF
Propofol. The American Society of Health-System Pharmacists. https://www.drugs.com/monograph/Propofol.html
Ruffle JK. Molecular neurobiology of addiction: what's all the (Δ)FosB about?. The American Journal of Drug and Alcohol Abuse. November 2014; 40(6):428–37. PMID 25083822. https://doi.org/10.3109/00952990.2014.933840
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Diprivan- propofol injection, emulsion. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cec3b97-5183-4a9d-accd-21e76c99d3dd
Profast, Injektionsvätska/infusionsvätska, emulsion 10 mg/ml. FASS.se. 26 September 2024. https://fass.se/health/product/20090909000014/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 07:37:31 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 07:37:27 |
| erowid | ok | 2026-11-20 07:37:29 |
| gsrs | ok | 2026-11-20 07:37:27 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014956) | 2026-11-20 07:37:27 |
| kegg | ok | 2026-11-20 07:37:29 |
| pubchem | ok | 2026-11-20 07:37:27 |
| missing (no r/tripreports posts mention it) | 2026-11-20 07:37:27 | |
| sider | ok | 2026-11-20 07:37:27 |
| structure | ok | 2026-11-20 07:37:27 |
| wikipedia | ok | 2026-11-20 07:37:27 |